Literature DB >> 28383694

Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.

Y Zhang1,2, L Zhang1, R Li1,2, D W Chang1, Y Ye1, J D Minna3, J A Roth4, B Han2, X Wu1.   

Abstract

BACKGROUND: Cancer initiation and development are driven by key mutations in driver genes. Applying high-throughput sequencing technologies and bioinformatic analyses, The Cancer Genome Atlas (TCGA) project has identified panels of somatic mutations that contributed to the etiology of various cancers. However, there are few studies investigating the germline genetic variations in these significantly mutated genes (SMGs) and lung cancer susceptibility. PATIENTS AND METHODS: We comprehensively evaluated 1655 tagged single nucleotide polymorphisms (SNPs) located in 127 SMGs identified by TCGA, and test their association with lung cancer risk in large-scale case-control study. Functional effect of the validated SNPs, gene mutation frequency and pathways were analyzed.
RESULTS: We found 11 SNPs in 8 genes showed consistent association (P < 0.1) and 8 SNPs significantly associated with lung cancer risk (P < 0.05) in both discovery and validation phases. The most significant association was rs10412613 in PPP2R1A, with the minor G allele associated with a decreased risk of lung cancer [odds ratio = 0.91, 95% confidence interval (CI): 0.87-0.96, P = 2.3 × 10-4]. Cumulative analysis of risk score built as a weight sum of the 11 SNPs showed consistently elevated risk with increasing risk score (P for trend = 9.5 × 10-9). In stratified analyses, the association of PPP2R1A:rs10412613 and lung cancer risk appeared stronger among population of younger age at diagnosis and never smokers. The expression quantitative trait loci analysis indicated that rs10412613, rs10804682, rs635469 and rs6742399 genotypes significantly correlated with the expression of PPP2R1A, ATR, SETBP1 and ERBB4, respectively. From TCGA data, expression of the identified genes was significantly different in lung tumors compared with normal tissues, and the genes' highest mutation frequency was found in lung cancers. Integrative pathway analysis indicated the identified genes were mainly involved in AKT/NF-κB regulatory pathway suggesting the underlying biological processes.
CONCLUSION: This study revealed novel genetic variants in SMGs associated with lung cancer risk, which might contribute to elucidating the biological network involved in lung cancer development.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  TCGA; eQTL; lung cancer; pathway analysis; significantly mutated genes; tagSNP

Mesh:

Substances:

Year:  2017        PMID: 28383694      PMCID: PMC5834153          DOI: 10.1093/annonc/mdx161

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  30 in total

1.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.

Authors:  Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston
Journal:  Nat Genet       Date:  2008-04-02       Impact factor: 38.330

2.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

3.  Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response.

Authors:  Dong Liang; Larissa Meyer; David W Chang; Jie Lin; Xia Pu; Yuanqing Ye; Jian Gu; Xifeng Wu; Karen Lu
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

4.  Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.

Authors:  Syed A Ali; Verline Justilien; Lee Jamieson; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

5.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.

Authors:  Shishir Shishodia; Dimpy Koul; Bharat B Aggarwal
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

6.  Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma.

Authors:  Eda Erdogan; Eric W Klee; E Aubrey Thompson; Alan P Fields
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

7.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

Review 8.  Multiple pathways regulated by the tumor suppressor PP2A in transformation.

Authors:  Jukka Westermarck; William C Hahn
Journal:  Trends Mol Med       Date:  2008-03-10       Impact factor: 11.951

9.  Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis.

Authors:  Jinmin Zhao; Hua Xu; Maolin He; Zhe Wang; Yang Wu
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  10 in total

1.  A Germline Mutation in ATR Is Associated With Lung Adenocarcinoma in Asian Patients.

Authors:  Guangyao Bao; Xiaojiao Guan; Jie Liang; Yao Yao; Yifan Xiang; Tian Li; Xinwen Zhong
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

Review 2.  Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Cancer Therapy.

Authors:  Hao-Yun Luo; Hai-Ying Shen; R Serene Perkins; Ya-Xu Wang
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

3.  Downregulation of SETBP1 promoted non-small cell lung cancer progression by inducing cellular EMT and disordered immune status.

Authors:  Hao-Ran Li; Jian Gao; Chun Jin; Jia-Hao Jiang; Jian-Yong Ding
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

4.  Novel ratio-metric features enable the identification of new driver genes across cancer types.

Authors:  Malvika Sudhakar; Raghunathan Rengaswamy; Karthik Raman
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Authors:  Xilin Hu; Hanlin Xu; Qianwen Xue; Ruran Wen; Wenjie Jiao; Kaihua Tian
Journal:  Mol Med       Date:  2021-10-07       Impact factor: 6.354

6.  Germline mutation analyses of malignant ground glass opacity nodules in non-smoking lung adenocarcinoma patients.

Authors:  Wenjun Mao; Ruo Chen; Rongguo Lu; Shengfei Wang; Huizhu Song; Dan You; Feng Liu; Yijun He; Mingfeng Zheng
Journal:  PeerJ       Date:  2021-08-31       Impact factor: 2.984

Review 7.  A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.

Authors:  Mohammed I El-Gamal; Nada H Mewafi; Nada E Abdelmotteleb; Minnatullah A Emara; Hamadeh Tarazi; Rawan M Sbenati; Moustafa M Madkour; Seyed-Omar Zaraei; Afnan I Shahin; Hanan S Anbar
Journal:  Molecules       Date:  2021-12-05       Impact factor: 4.411

8.  Prognostic Signature, Immune Features, and Therapeutic Responses of a Novel Ubiquitination-Related Gene Signature in Lung Adenocarcinoma.

Authors:  Muge Xu; Jiening Gong
Journal:  J Oncol       Date:  2022-08-16       Impact factor: 4.501

9.  The Role of SETBP1 in Gastric Cancer: Friend or Foe.

Authors:  Fujin Fang; Chengyou Liu; Qiong Li; Rui Xu; Tiantian Zhang; Xiaobing Shen
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

10.  Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.

Authors:  Donghai Xiong; Jing Pan; Yuxin Yin; Hui Jiang; Eva Szabo; Ronald A Lubet; Yian Wang; Ming You
Journal:  Oncotarget       Date:  2017-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.